Abstract: Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

Abstract: This invention comprises a chlorophyllin composition and method of administering the same for using the same for treatment of kidney disease patients to achieve decrease in serum creatinine level. The chlorophyllin composition and its method of administration is also for concurrent increase in blood hemoglobin level. The Chlorophyllin is selected from the group consisting of sodium copper chlorophyllin, Potassium copper chlorophyllin, Potassium Iron chlorophyllin and other metal containing chlorophyllin/s. To the chlorophyllin composition are added additives, optionally, (a) a diluent, excipient or a carrier, and optionally (b) the chlorophyllin composition is administered, either concurrently, sequentially or in any other order, with other ingredients/compositions supportive for kidney function. The dosage form of composition comprises a liquid, powder, tablet and a capsule. A kit is also provided comprising the chlorophyllin composition and the additional ingredients.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine in combination with one or more quaternary compounds or silicon quaternary compounds, one or more guanide-containing compounds, one or more alcohols, one or more metallic particles, one or more metal salts, or any combination thereof. The present specification further discloses a kit comprising, consisting essentially of, or consisting of a one or more containers including a composition disclosed herein or components which make up such compositions as well as methods and uses for such compositions and kits.

Abstract: A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.

Abstract: The present disclosure provides systems and methods for producing saturated oxygen water. The present disclosure also provides methods of increasing a concentration of dissolved oxygen in blood of a human subject.

Abstract: Methodology for encouraging hair growth in male humans, and more particularly to methodology which involves application of electromagnetic radiation, mechanical vibrations, along with applications of combined minoxidil, mint oil, (preferably menthol containing essential peppermint oil), ginger oil, lavender oil, castor bean oil, jojoba oil; melaleuca oil, cumin oil, D-alpha tocopherol (vitamin E) infused oil, biotin infused oil and a single selection, or dry mixture and/or liquid “tea” formed from selections from the group consisting of powdered saw palmetto; powdered horsetail; powdered ginger; powdered stinging nettles; powdered horny goat weed; powdered pueraria lobate; powdered Tribulus terrestris; powdered ashwagandha; powdered capsicum; powdered habenero; powdered green tea; powdered sage; powdered gingko biloba; powdered myrrh; powdered alpha-hydroxy; powdered Aloe vera; powdered wheat protein; powdered wheat starch; powdered casein, powdered keratin, powdered folic acid; powdered fenugreek seed and po

Abstract: Provided are compositions and methods for preventing, mitigating, decreasing, inhibiting and/or reversing bone loss and/or increasing and/or promoting bone regeneration and remodeling and/or preventing, mitigating, decreasing, inhibiting and/or reversing periodontitis and/or periodontal disease in a subject by administering to the subject an effective amount of an inhibitor of soluble epoxide hydrolase (sEH).

Abstract: A dental liner and a manufacturing method therefor are disclosed. The dental liner is a dental liner for coupling feldspar porcelain and zirconia and includes: silicon dioxide; aluminum oxide; 1,4-butanediol for maintaining the moisture of the dental liner and preventing the generation of layers; and a zirconia powder for coupling the dental liner and zirconia by strengthening chemical bonding of the dental liner and zirconia.

Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one of quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.

Abstract: A method for killing arthropods may include providing a mineral composition to a substrate that arthropods will contact, wherein the mineral composition is not a carrier for chemical toxin. The mineral composition may include an aluminosilicate particulate, wherein contact between the mineral composition and an arthropod results in death of the arthropod. A composition for killing arthropods may include a mineral composition for associating with a substrate. The mineral composition may include at least one of an aluminosilicate particulate and a diatomaceous earth particulate, wherein the mineral composition is not a carrier for a chemical toxin. The mineral composition may have a median particle size d50 of 10 ?m or less. A system for killing arthropods may include a mineral composition including at least one of an aluminosilicate particulate and a diatomaceous earth particulate. The system may further include a substrate, wherein the mineral composition is associated with the substrate.

Abstract: Devices and methods analyze daily hydration in an individual. An application can confirm if typical daily water intake by an individual participating is sufficient to maintain hydration and/or can determine an optimal personalized hydration plan to maintain or improve hydration for the individual. The application can estimate water losses during each of a plurality of activities by considering one or more characteristics of the individual, such as weight, height, gender, heart rate at rest, maximal heart rate, VO2 max, effort intensity, and type of clothes worn, and/or one or more characteristics of each of the plurality of activities, such as the specific category of activity, the time duration, and the location of each of the plurality of activities (e.g., ambient temperature and moisture). The daily hydration plan can improve daily performance by the individual, for example one or more of decreased fatigue, increased motivation, improved mood, or better cognitive functioning.

Abstract: The present invention relates to a disinfectant composition comprising hydrogen peroxide and silver ions in association with at least one quaternary ammonium salt with biocidal action and compatible with silver ions. The composition can be used for disinfecting a room and any objects contained therein, in particular healthcare environments, such as, for example, laboratories, doctors' surgeries, hospital rooms, ambulance compartments and the like, where it is important to have a biocidal activity at low dosages proportional to the average contamination present.

Abstract: The use of chlorine dioxide (CLO2) to kill or disable pathogens such as viruses, particularly those of the Coronavirus family. A certain amount of CLO2 is used via different modalities, particularly through one's nose or mouth, as a therapeutic. CLO2 can treat, cure and/or prevent diseases, such as methicillin resistant Staphylococcus aureus (MRSA), fungal infections, the common cold, and more particularly a current disease in the year 2020, known as COVID-19. The invention will not only kill or disable SARS CoV-2, which causes COVID-19, but will also kill or disable the next Coronavirus, SARS CoV-3, once CoV-2 mutates and escapes any vaccine against it.

Abstract: Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile acid level and delivering a composition effective to modulate the bile acid level. A method for modulating a bile acid profile includes comparing a bile acid profile to a target profile and delivering a bile acid cocktail to increase bile acid levels. In another embodiment, a pharmaceutical composition for increasing bile acid levels includes a bile acid cocktail effective to increase bile acid levels. The composition is further useful as part of an implantable system.

Abstract: Embodiments described herein generally relate to liquids, such as aqueous solutions, that contain hydrogen gas and palmitoylethanolamide. In certain cases, the liquids may also include active pharmaceutical agents (e.g., cannabinoids), noble gases, and/or other additives. Such liquids may be useful, for example, for increasing a subject's physical energy levels, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like. Some embodiments relate to liquids disposed within a container (e.g., a sealed container), such that the liquid comprises hydrogen gas and palmitoylethanolamide dissolved or otherwise contained (e.g., suspended and/or infused) in the liquid. The liquids (e.g., aqueous solutions) described herein may be orally administered to a subject (e.g., drunk by a subject). In certain embodiments, the hydrogen gas and/or palmitoylethanolamide may be present in the liquid at a particular concentration (e.g., a physiologically relevant concentration).

Abstract: Disclosed herein are methods and compositions for treating, inhibiting, or ameliorating pulmonary infections, including cystic fibrosis. Aspects described herein relate to compositions including a saline solution and hypochlorite and methods of using these compositions alone or in combination with additional compounds, including antibiotics, an anti-inflammatories, bronchodilators, mucolytics, or oxygen therapy for treating, ameliorating, or inhibiting a pulmonary infection, including cystic fibrosis.

Abstract: A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.

Abstract: The invention is directed to products and methods for preparing self-seeding vascular constructs generated as a bi-layered electrospun matrices, conjugated with EPC-specific antibodies and anti-thrombogenic agents on the inner surfaces of their lumens.

Abstract: A method for production of solid water particles for homeopathy uses principles of quantum physics to from a concentrated solid water particle solution. A homeopathic ingredient solution is diluted in purified water in an inert gas environment. The dilution occurs as infinitesimal doses, in which the solution is repetitively diluted in water past the point where few molecules from the solution remain. An electrical field is applied to align the water molecules for formation of a large clump of solid water particles. Alternating phases of ultrasonic vibrations break down the large clump into small clusters of solid water particles. The vibration is followed by periods of rest, whereby the small clusters grow into successively larger clumps by absorbing water molecules. The vibrations and resting are repeated in cycles until a desired concentration of solid water particles form in the solid water particle solution.

Abstract: The present invention relates to a forming material for three-dimensional (3D) printing, a forming method for 3D printing, and a formed object, wherein, while being based on an amorphous glass powder shaped irregularly, the forming material for 3D printing ensures excellent flowability and sinterability such that it enables the formation of high-quality products at high speed. The forming material for 3D printing consists of a parent glass powder in the form of an unmelted powder irregularly shaped by crushing amorphous glass; and a spherical nanopowder that has an average particle diameter equal to or less than 1/50th of the average particle diameter of the parent glass powder and is mixed in such a way that it can be disposed on a surface of the parent glass powder to enhance the flowability of the irregularly shaped parent glass powder during the formation of an object by 3D printing.

Abstract: Disclosed are compositions and methods that include or utilize plant growth promoting rhizobacteria (PGPR) for improving growth and health in plants and animals. The compositions and methods include or utilize a plant growth promoting rhizobacteria (PGPR) that expresses a protein associated with pectin metabolism, and a saccharide comprising pectin or a pectin-related saccharide.

Abstract: The technology relates to nutritional supplements containing one or more minerals. In particular the technology relates to nutritional supplements comprising filamentous fungal biomass and one or more minerals selected from zinc, magnesium, selenium, chromium, copper and manganese, and a process to make the nutritional supplements.

Abstract: An improved manufacturing process produces microcrystalline hydroxyapatite with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.

Abstract: A method for controlling xylophages (e.g., termites, Asian Beetle, Emerald Ash borer, Weevils, Deathwatch Caterpillars, cockroaches) by inhibiting methane production of methanogenic Archaea in the digestive tract thereof. The inhibiting of the critical biochemical pathways specific to the methanogenic Archaea is achieved by contacting the xylophage with one or more antimethanogenic reagent (AMR) compounds. The AMRs may include, for example, naturally-occurring statins (which may be found in red yeast rice) or derivatives thereof, linoleic acid or related compounds, essential oils, certain synthetic compounds or combinations thereof. As a result, the effectiveness of the methanogenic Archaea to produce methane is compromised. This subsequently results into the malfunctioning of the xylophages' digestive system and provides a safe, natural, green and sustainable means of controlling the xylophages.

Abstract: The invention relates to probiotic bacteria and particularly, although not exclusively, to anti-bacterial compositions derived from probiotic bacteria. Disclosed are compositions comprising material secreted from probiotic bacteria, uses thereof, and methods using the compositions. Particularly contemplated are compositions comprising material secreted from Lactobacillus rhamnosus, and uses thereof.

Abstract: The present invention relates to conjugated linoleic acid (CLA)-producing strains of probiotic bacteria. In particular, the present invention relates to a selection of bacterial strains belonging to the genus Bifidobacterium which were selected for their ability to produce conjugated linoleic acid (CLA) from linoleic acid (LA). Furthermore, the present invention relates to a food, dietetic or pharmaceutical composition comprising said bacterial strains capable of increasing the quantity of CLA in situ, i.e. inside the gastrointestinal tract.

Abstract: The present invention relates to a plant disease control agent containing a compound represented by the following formula (1) or salt thereof as an active ingredient (in the formula, R1 and R2 represents a hydrogen atom or methyl group but excepting cases where R1 and R2 are the same), a plant disease controlling method applying the plant disease control agent on plants suffering from diseases, and a novel compound represented by formula (1) or salt thereof.

Abstract: The present invention relates to methods for attenuating aging, of health maintenance, and/or treating, or delaying the onset of, an age-related condition or disorder, in a subject comprising administering to the subject an effective amount of (a) one or more compounds that sustain pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion and (b) one or more chelators. A further aspect of the invention is a composition comprising (a) and (b).

Abstract: An article having anti-microbial effect is provided. The article includes an occlusive layer; a substrate having two opposing major surfaces, wherein one opposing major surface is a nanostructured surface; a metal oxide layer, wherein the nanostructured surface is coated with the metal oxide layer and the metal oxide layer comprises a metal oxide; and a metal layer overlaying the metal oxide layer.

Abstract: Implementations of a topical homeopathic formulation may include an active portion including a plurality of active ingredients and a base including a plurality of inactive ingredients. The plurality of active ingredients may include one of tinctures and homeopathic preparations of Apis mellifica, Arnica montana, Atropa belladonna, Bellis perennis, Bryonia alba, Cactus grandifloras, Caulophyllum thalictroides, Cimicifuga racemose, Citrullus colocynthis, Cyclamen europaeum, Gelsemium Sempervirens, Gnaphalium polycephalum, Jonesia asoca, Juniperus Sabina, Kali carbonicum, Lilium tigrinum, Rhamnus californica, Tilia europaea, Viburnum opulus, and any combination thereof.

Abstract: The invention relates to an emulsion containing a mixture of an aqueous phase and an oil phase, wherein the aqueous phase comprises seawater, a viscosifier, and a humectant, and wherein the oil phase comprises polyglyceryl, hectorite, propylenecarbonate, t-butyl alcohol, a polyacrylate crosspolymer-6, at least one viscosifier, at least one emulsifier, at least one co-emulsifier, and at least one emollient, such that the phases forming the emulsion are stabilized. Another object of the present invention is the method of manufacture, which allows producing the emulsion with seawater described herein in detail.

Abstract: Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500.

Abstract: This document provides bacterial compositions. For example, bacterial compositions having a combination of different bacterial strains formulated in a manner to maintain the stability of the bacteria are provided.

Abstract: Redox signaling gels are disclosed. Such gels include a composition with at least one reactive oxygen species (ROS) and a rheology modifier. Also presented herein is a process for making the gels which includes making the composition by taking the steps of purifying water to produce ultra-pure water, combining a salt to the ultra-pure water to create a salinated water, electrolyzing the salinated water at a temperature of 4.3 to 5.8° C. such that the electrolyzing is accomplished with an anode, cathode and power source such that the power source comprises a transformer and a rectifier and does not comprise a filter capacitor.

Abstract: A system and method includes delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and the perfluorocarbon liquid comprises of an anti-inflammatory in a perfluorocarbon liquid and wherein the reactive species may include, alone or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin.

Abstract: Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

Abstract: Embodiments of the present disclosure provide systems and devices for delivering gaseous Nitrous Oxide (gNO) under therapeutic parameters to reduce infection in a subject. Certain embodiments include devices and systems for delivering pressurized gNO to reduce bioburden and promote healing in the wounds of subjects having various disease conditions, including skin and soft tissue infections (SSTIs) and osteomyelitis. In some embodiments, the present disclosure provides portable wound healing devices for delivering pressurized gNO to the site of a wound to treat various disease conditions in a subject.

Abstract: A treatment product for a mouth-related disorder, and associated method of treatment, where the treatment product includes an initially sealed dispensing package and a composition disposed in said package, the composition including one or more vitamins, one or more amino acids, and Xylitol (a natural composition), where the composition is a liquid at room temperature and solid or substantially solid when administered to a subject's mouth.

Abstract: The present invention relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against influenza virus. The present invention also relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against drug-resistant influenza virus strains. The present invention is further related to a method for treating influenza in a subject, comprising administering to said subject an effective amount of mycophenolate mofetil or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to methods of preparing stable suspensions of precious metal nanoparticles and methods for attaching bio-molecules to the nanoparticles. The formation of nanoparticles can be accomplished by either chemical synthesis or pulsed laser ablation in a liquid. The present disclosure reveals the importance of controlling the conductivity of the dispersion medium during pulsed laser ablation in a liquid to control the particle size of the nanoparticles. The present disclosure also reveals the importance of adjusting and maintaining the conductivity in a range of 25 ?S/cm or less during storage of the nanoparticles and just prior to performing bioconjugation reactions. The control of conductivity is an important process for maintaining the nanoparticles as a stable non-aggregated colloidal suspension in a dispersion medium.

Abstract: A gas enriched foam generating apparatus for performing medical procedures includes a foam generating tip assembly composed of a multi-channel arrangement at a proximal first end thereof and a tip at a distal second end thereof. The apparatus also includes a compressed gas unit fluidly connected to the multi-channel arrangement at a proximal first end of the foam generating tip assembly and a medical solution fluidly connected to the multi-channel arrangement at a proximal first end of the foam generating tip assembly. Compressed gas, from the compressed gas unit, and the medical solution are combined within the foam generating tip assembly in a manner generating a gas enriched foam that is ultimately dispensed from the foam generating apparatus.

Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

Abstract: [Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided. [Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present disclosure is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present disclosure is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per liter ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.

Abstract: The present invention relates to dissolved silicate compositions in which the dissolved silicate is stabilized by at least two selected osmolytes and is therefore bioavailable. The composition and its dilutions are stable over a long period of time and are used in a wide field of applications for the benefit of living organisms such as plants, animals and humans.

Abstract: Embodiments of the invention relate to a composition, method and kit for producing galvanic cells upon application of the composition to the skin. In some embodiments, the composition comprises encapsulated half-galvanic cell units (e.g. individual and/or autonomous half-galvanic cell units) having the same ox/red potential (E°), wherein each half-galvanic cell unit comprises metal particles in the range of nano- to micro size or a mixture thereof, suspended within an aqueous solution of soluble electrolytic salt of same metal and wherein each half-galvanic cell unit is encapsulated by internal layer(s) made of hydrophilic metal (including silicon) oxide nanoparticles and external layer(s) made of hydrophobic metal (including silicon) oxide nanoparticles. The composition is useful for preventing and/or treating alopecia or for enhancing hair growth.

Abstract: A method for manufacturing a parasiticidal composition comprising at least 40% of alkali metal bicarbonate and at least 1% of silica, wherein: at least 35% of the alkali metal bicarbonate of the composition is milled in the presence of silica in order to form a mixture of particles, and if necessary, the remainder of the alkali metal bicarbonate is added to the mixture of particles to form the parasiticidal composition, and wherein said parasiticidal composition has a particle size distribution such that at least 50% by weight of the particles have a diameter of less than 100 ?m. A parasiticidal composition obtained by the present method and the use of the parasiticidal composition obtained by the present method in the form of a powder, a suspension or a gel.

Abstract: A medical device has a surface intended for contact with living tissue, wherein the surface comprises nanoparticles comprising a non-toxic post-transition metal such as gallium and/or bismuth, said nanoparticles having an average particle size of 500 nm or less. The nanoparticles may provide an antimicrobial effect, and thus the risk for infection may be reduced.

Abstract: The present invention is directed to diclofenac sublingual spray formulations. The present invention is also directed to methods for treating pain and inflammation by administering the formulations of the present invention to patients in need thereof.

Abstract: A sanitizing formulation is disclosed for use as a hand sanitizer. The formulation may include hypochlorous acid, a silicone polymer or blend thereof, sodium phosphate, hydrochloric acid, and sodium magnesium silicate. Methods of using and making the sanitizing formulation are also disclosed.